PUMA BIOTECHNOLOGY, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for PUMA BIOTECHNOLOGY, INC. (PBYI), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are PBYI insiders buying or selling?
In the last 12 months, PUMA BIOTECHNOLOGY, INC. insiders reported 0 open-market purchases ($0) and 14 sales ($2.1M) — net selling of $2.1M. Since January 2018, Trabud has recorded 231 Form 4 filings for PBYI: 1 buys ($62.1K) and 230 sells ($11.2M).
Source: SEC EDGAR Form 4
What stands out
- No PUMA BIOTECHNOLOGY, INC. insider made an open-market purchase in the last 12 months; the 14 reported open-market sales totaled $2.1M.
Key Statistics (January 2018 – Sep 17, 2026)
Total Form 4 filings
231
SEC EDGAR
Insider filers
16
Insider buys (1)
$62.1K
Insider sells (230)
$11.2M
Insider sentiment
Net sellingNet insider flow of $11.1M in net selling since January 2018, and $2.1M in net selling over the last 12 months.
Recent PBYI insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Troy Edward Wilson | Director | Sale | 5.0K | $9.10 | $45.5K | SEC ↗ |
| Sep 17, 2026 | Alessandra Cesano | Director | Sale | 62.1K | $9.12 | $567.0K | SEC ↗ |
| Jul 9, 2026 | Alan H Auerbach | President and CEO | Sale | 44.1K | $8.26 | $364.1K | SEC ↗ |
| Jul 9, 2026 | Douglas M Hunt | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | Sale | 8.5K | $8.26 | $69.9K | SEC ↗ |
| Jul 9, 2026 | Maximo F Nougues | Chief Financial Officer | Sale | 9.4K | $8.26 | $77.6K | SEC ↗ |
| Jun 16, 2026 | Troy Edward Wilson | Director | Sale | 10.8K | $7.20 | $77.7K | SEC ↗ |
| Jun 16, 2026 | Brian M Stuglik | Director | Sale | 8.1K | $7.20 | $58.3K | SEC ↗ |
| Jun 16, 2026 | Adrian Senderowicz | Director | Sale | 27.0K | $7.20 | $194.3K | SEC ↗ |
| Jun 16, 2026 | Jay M Moyes | Director | Sale | 22.0K | $7.22 | $158.8K | SEC ↗ |
| Jun 16, 2026 | Allison Dorval | Director | Sale | 11.6K | $7.20 | $83.6K | SEC ↗ |
| Jan 9, 2026 | Alan H Auerbach | President and CEO | Sale | 35.0K | $5.86 | $204.9K | SEC ↗ |
| Jan 9, 2026 | Douglas M Hunt | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | Sale | 9.0K | $5.86 | $52.7K | SEC ↗ |
| Jan 9, 2026 | Maximo F Nougues | Chief Financial Officer | Sale | 10.9K | $5.86 | $64.2K | SEC ↗ |
| Nov 13, 2025 | Michael Patrick Miller | Director | Sale | 20.0K | $4.86 | $97.2K | SEC ↗ |
| Jul 22, 2025 | Alessandra Cesano | Director | Sale | 27.0K | $3.37 | $90.9K | SEC ↗ |
| Jul 11, 2025 | Maximo F Nougues | Chief Financial Officer | Sale | 9.5K | $3.53 | $33.6K | SEC ↗ |
| Jul 11, 2025 | Douglas M Hunt | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | Sale | 7.8K | $3.53 | $27.6K | SEC ↗ |
| Jul 11, 2025 | Alan H Auerbach | President and CEO | Sale | 47.2K | $3.53 | $166.7K | SEC ↗ |
| Jun 17, 2025 | Troy Edward Wilson | Director | Sale | 10.8K | $3.40 | $36.7K | SEC ↗ |
| Jun 17, 2025 | Brian M Stuglik | Director | Sale | 8.1K | $3.39 | $27.5K | SEC ↗ |
| Jun 17, 2025 | Adrian Senderowicz | Director | Sale | 27.0K | $3.40 | $91.8K | SEC ↗ |
| Jun 17, 2025 | Jay M Moyes | Director | Sale | 22.0K | $3.40 | $74.8K | SEC ↗ |
| Jun 17, 2025 | Allison Dorval | Director | Sale | 11.6K | $3.40 | $39.5K | SEC ↗ |
| Jun 17, 2025 | Alessandra Cesano | Director | Sale | 12.2K | $3.40 | $41.3K | SEC ↗ |
| Jan 4, 2025 | Maximo F Nougues | Chief Financial Officer | Sale | 10.2K | $3.15 | $32.2K | SEC ↗ |
Showing the 25 most recent of 231 Form 4 filings for PUMA BIOTECHNOLOGY, INC..
Most active PBYI insiders
- Alan H Auerbach60 filings
- Douglas M Hunt37 filings
- Maximo F Nougues33 filings
- Richard Paul Bryce32 filings
- Alvin F Wong9 filings
Ask anything about PBYI insider activity
Use Trabud's AI agent to query PUMA BIOTECHNOLOGY, INC.'s Form 4 history in plain English — "Show me PBYI CEO purchases this year" or compare it against any other ticker.
Open the AI agentPBYI insider trading FAQ
Are PUMA BIOTECHNOLOGY, INC. insiders buying or selling?
In the last 12 months, PUMA BIOTECHNOLOGY, INC. insiders reported 0 open-market purchases ($0) and 14 sales ($2.1M) — net selling of $2.1M. Since January 2018, Trabud has recorded 231 Form 4 filings for PBYI: 1 buys ($62.1K) and 230 sells ($11.2M). Over the full record that is net selling of $11.1M.
How many insiders trade PBYI stock?
16 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for PUMA BIOTECHNOLOGY, INC.. The most recent filing was accepted on Sep 17, 2026.
Where does Trabud get PBYI insider trading data?
All PBYI insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.